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Abstract
Application of photodynamic therapy for treating cancers has been restrained by suboptimal 
delivery of photosensitizers to cancer cells. Nanoparticle (NP)-based delivery has become an 
important strategy to improve tumor delivery of photosensitizers; however, the success is still 
limited. One problem for many NPs is poor penetration into tumors, and thus the photokilling is 
not complete. We aimed to use chemical conjugation method to engineer small NPs for superior 
cancer cell uptake and tumor penetration. Thus, Chlorin e6 (Ce6) was covalently conjugated to 
PAMAM dendrimer (generation 7.0) that was also modified by tumor-targeting RGD peptide. 
With multiple Ce6 molecules in a single nanoconjugate molecule, the resultant targeted 
nanoconjugates showed uniform and monodispersed size distribution with a diameter of 28nm. 
The singlet oxygen generation efficiency and fluorescence intensity of the nanoconjugates in 
aqueous media were significantly higher than free Ce6. Targeted nanoconjugates demonstrated 
approximately 16-fold enhancement in receptor-specific cellular delivery of Ce6 into integrin-
expressing A375 cells compared to free Ce6 and thus were able to cause massive cell killing at 
low nanomolar concentrations under photo-irradiation. In contrast, they did not cause significant 
toxicity up to 2μM in dark. Due to their small size, the targeted nanoconjugates could penetrate 
deeply into tumor spheroids and produced strong photo-toxicity in this 3-D tumor model. As a 
result of their great cellular delivery, small size, and lack of dark cytotoxicity, the nanoconjugates 
may provide an effective tool for targeted photodynamic therapy of solid tumors.
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1. Introduction
Photodynamic therapy (PDT) is a clinically approved and minimally invasive therapeutic 
procedure, which is based on the combined use of a photosensitizer (PS), oxygen, and light 
radiation. PSs are usually pharmacologically inactive in the dark and are activated by 
irradiation at a specific wavelength to produce reactive oxygen species (ROS), which are 
capable of rendering cancer cell death.[1] Clinical use of many PSs has been hampered by 
their intrinsic limitations including poor solubility, aggregation in aqueous solution, and 
poor tumor selectivity.[2] To overcome these limitations, various nanoparticles (NPs), 
including liposomes, inorganic NPs and polymeric NPs, have been developed to increase 
water solubility and enhance tumor delivery of PSs.[3–8] Among these NPs, various 
polymer-PS conjugates, such as Pluronic F127/Ce6 and glycol chitosan/pheophorbide A 
conjugates, have been reported.[9, 10] Chemical conjugation of hydrophobic photosensitizer 
to hydrophilic polymers allows self-assemble into NPs. Importantly, chemical conjugates 
demonstrate higher solubility and increased stability in vitro and in vivo than free PSs.[3–7] 
Further, chemical conjugation method can avoid the release of PSs from NPs before 
reaching to the target tissues and thus reduces side effects caused by accumulation of PSs in 
non-target tissues.[9, 11, 12]
Poor tumor penetration is still a limitation for NP-based delivery of PSs. For complete 
eradication of solid tumors, anticancer drugs including PSs should penetrate deeply in the 
solid tumors and reach all cancer cells in a therapeutic concentration.[13] Abraxane is a 
FDA-approved albumin-bound paclitaxel NP for treatment of solid tumors. Their large size 
(about 130 nm) allows them to preferentially accumulate in solid tumors by the Enhanced 
Permeability and Retention (EPR) effect.[13–15] However, although it causes lower side 
effects than free paclitaxel, this NP only provides modest survival benefits, likely due to 
poor penetration of Abraxane into deep tumor tissues.[13, 16] It has been reported that NPs 
smaller than 50nm may penetrate into deep tissue far from tumor vasculature.[13, 17, 18] 
However, most of the NPs that are used for delivery of PSs are too large for effective tumor 
penetration. For example, liposomes and albumin NPs that are prepared via complexation 
are typically larger than 100nm.[7, 19] Those prepared by chemical conjugation, though 
smaller than liposomes, are still larger than 50nm.[9, 10]
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This study aimed to use chemical conjugation method to construct NPs that are cancer cell-
selective and are smaller than 50nm. Thus, the resultant NPs can deliver PSs deeply into 
tumor tissues and effectively into cancer cells. For this purpose, we chose poly (amido 
amine) generation 7.0 (PAMAM G7) dendrimer with a diameter of 8nm as a core molecule 
to prepare ultra-small NPs. By modification with sufficient PEG on the surface, PAMAM 
dendrimers showed reduced cytotoxicity. In addition, to achieve tumor selectivity, cRGD, a 
ligand to integrin αvβ3 that is overexpressed in many cancer cells,[20] were functionalized to 
the surface of PEGylated PAMAM dendrimers. Photosensitizer Ce6 were covalently 
conjugated onto the RGD functionalized PAMAM and the resultant nanoconjugates (RGD-
P-Ce6) were characterized in terms of size, zeta potential, fluorescence and singlet oxygen 
generation efficiency. We then examined cellular delivery and phototoxicity of the 
nanoconjugates in integrin αvβ3-expressing A375 cells, and further studied their penetration 
and phototoxicity in spheroids of A375 cells, a 3-D model of solid tumors.
2. Materials and Methods
2.1 Preparation of RGD-P-Ce6
PAMAM G7 (Sigma-Aldrich, St. Louis, MO) was conjugated with Mal-PEG5K-NHS 
(Nanocs Inc., New York, NY) at a 1:30 molar ratio of PAMAM to PEG in PBS (pH 7.4) for 
30min at room temperature, and this was followed by adding cRGDyC peptide (Peptides 
International, Inc., Louisville, KY) to react with the maleimide group on PEG at the ratio of 
RGD to PAMAM as 40:1 to obtain RGD-PAMAM (RGD-P). Ce6 (MedKoo Biosciences 
Inc., Chapel Hill, NC) was dissolved in DMSO, followed by the addition of 10 molar 
equivalents of EDC and Sulfo-NHS (Thermo Fisher, Rockford, IL). After 3 hrs, activated 
Ce6 (Ce6-NHS) was added into the above RGD-PAMAM solution with a 15:1 molar ratio 
of Ce6 to PAMAM. The reaction was gently stirred for 12 hrs in dark at room temperature. 
For the purification, crude nanoconjugates were chromatographed using Sephadex LH-20 
(GE Healthcare, Pittsburgh, PA) to remove unreacted Ce6, and mobile phase was mixture of 
methanol and distilled water (v/v=1:2). After that, the resulting product was purified by gel 
filtration using Sephadex G100 (GE Healthcare) and PBS was used as mobile phase. In 
addition, monofunctional PEG5K-NHS (Nanocs Inc.) was used for preparation of non-
targeting nanoconjugates PEG-P-Ce6 with similar method (Sfig. 1).
2.2 Characterization of RGD-P-Ce6
The Ce6 content in the RGD-P-Ce6 nanoconjugates was measured by NanoDrop 1000 
Spectrophotometer (Thermo Scientific). Free Ce6 dissolved in DMSO was used as standard 
solution and the amount of Ce6 of RGD-P-Ce6 (diluted with methanol) was measured as the 
absorption at the 405nm peak. The fluorescence of Ce6 and RGD-P-Ce6 were detected by 
NanoDrop 3300 (Thermo Scientific).
To evaluate the singlet oxygen generation (SOG) by light irradiation of the nanoconjugates, 
the singlet oxygen sensor green (SOSG, Life Technologies, Carlsbad, CA) was mixed with 
RGD-P-Ce6 or free Ce6 in PBS with all concentrations at 1μM. SOG was induced by 
irradiation at a light intensity of 3.5 mW/cm2 using a 660 nm laser module diode 
(LaserLands, Wuhan, China) equipped with a concave lens (Edmund Optics Inc., NJ). After 
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irradiation, SOSG fluorescence was measured at an excitation and emission of 488nm and 
525nm using FLUOstar Omega plate reader (BMG Labtech, Germany). PBS with SOSG 
was irradiated and served as a negative control.
The hydrodynamic sizes of the nanoconjugates were measured by dynamic light scattering 
using a Zetasizer Nano (Malvern Instruments, Malvern, UK). The zeta potentials were also 
measured using this instrument. The final Ce6 concentration of the nanoconjugates was 
adjusted to 20μM in DI water in these measurements. The morphology of the RGD-P-Ce6 
nanoconjugates was observed using a cryo-Transmission Electron Microscope (TEM, 
Oberkochen, Germany). In this experiment, the nanoconjugates were diluted and dropped on 
200 mesh carbon coated copper grids and were allowed to attach for 2min. Uranyl acetate 
aqueous solution (4%) was dropped on the grid to counterstain the nanoconjugates.
2.3 Cell culture and intracellular uptake
A375 cells (a non-pigmented melanoma cell line) and NIH3T3 cells (mouse fibroblasts) 
were cultured in DMEM medium supplemented with 10%FBS and 1% penicillin/
streptomycin at 37°C with 5% CO2.
To compare the intracellular uptake, A375 cells and NIH/3T3 cells were treated with free 
Ce6, PEG-P-Ce6 and RGD-P-Ce6 (150nM equivalent Ce6) for 12hrs. Then the cells were 
trypsinized and analyzed by flow cytometry using BD LSR II, with a 405nm laser and a 
670/20nm emission filter set for Ce6 fluorescence. To investigate the endocytosis 
pathway[21], A375 cells were pre-treated with various inhibitors (dynasore 30μM, 
chlorpromazine 12.5μM, filipin 5μg/ml, methyl-β-cyclodextrin 1.3mg/ml, amiloride 100μM 
and wortmannin 100nM) for 30 min and followed by incubation with RGD-P-Ce6 (100nM 
of Ce6) in the presence of the inhibitors for 4 hrs. After washing with PBS, the cells were 
trypsinzed and the Ce6 fluorescence intensity was measured using flow cytometry. To 
determine whether the cellular uptake of RGD-P-Ce6 is energy dependent, A375 cells was 
incubated with RGD-P-Ce6 (100nM) for 4 hrs at 4°C and the cellular uptake was compared 
to that at 37°C.
2.4 Intracellular trafficking of RGD-P-Ce6
Live cell confocal microscopy was performed to examine subcellular distribution of the 
targeted nanoconjugates. After cultured in glass-bottom dishes overnight, A375 cells were 
treated with RGD-P-Ce6 (400nM of Ce6) for 6 hrs. The cells were then treated with 
lysosomal marker Lysotracker Green DND-26 (75nM), ER tracker green (1μM) or 
transferrin-Alexa 488 (25μg/ml) for 1 hr. After washing twice with PBS, images were 
captured using an Olympus FV1200 confocal microscope.
2.5 Intracellular singlet oxygen detection after photo-irradiation
After incubated with RGD-P-Ce6 (75nM) for 12 hrs, A375 cells were further incubated with 
10μM CM-H2DCFDA (Life Technologies) for 60 min and were irradiated with a 660 nm 
laser (3.5mW/cm2) for 0, 10, 20 or 30 min. After that, the cells were harvested and the 
fluorescence of the cells was detected by flow cytometry (FITC channel) to measure the 
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intracellular ROS level.[22] In addition, the intracellular ROS was also detected by 
observing DCF using confocal microscopy.
2.6 Apoptosis after photo-irradiation
After treated with RGD-P-Ce6 (50nM of Ce6) for 12 hrs, A375 cells were rinsed twice with 
culture medium and photo-irradiated with a 660nm laser (3.5mW/cm2) for 30min. At 10min, 
4hrs or 12hrs post photo-irradiation, the cells were trypsinized and then stained with 
Annexin V FITC/PI (Life Technologies) according to the manufacturer’s instruction. The 
fluorescence of FITC and PI was detected with flow cytometry using a LSR II cell analyzer.
2.7 PDT induced lysosomal leakage
To detect the mechanism of apoptosis, lysosomal membrane permeabilization caused by 
photo-irradiation was visualized using confocal microscopy. After treatment of RGD-P-Ce6 
(75nM) and Alexa 488-Dextran (10kD, 200μg/ml) for 4 hrs, A375 cells were rinsed with 
PBS and incubated for another 1 hr before photo-irradiation (660nm laser, 3.5mW/cm2 and 
30min). Then, images were captured with an Olympus FV1200 Confocal Microscope.
2.8 Phototoxicity of RGD-P-Ce6
A375 and NIH3T3 cells (4,000 cells per well in 96-well plates) were incubated with free 
Ce6, PEG-P-Ce6 and RGD-P-Ce6 (25, 50, 100, 200 and 400nM) at 37°C for 12hrs. Then 
cells were rinsed with fresh culture medium and photo-irradiated with 660nm laser 
(3.5mW/cm2) for 30min. After 48hrs, cell viability was measured using Alamar blue Assay. 
Alamar blue was added into each well and incubated for 2 hrs, and then was detected using 
FLUOstar Omega (BMG Labtech, Germany). In addition, toxicity of free Ce6, PEG-P-Ce6 
and RGD-P-Ce6 without light irradiation was also measured using Alamar Blue assay.
To investigate the effect of light dose on the photokilling of RGD-P-Ce6, A375 cells were 
incubated with 100nM of RGD-P-Ce6 in the dark for 12hrs and then rinsed twice with fresh 
culture media. After that, the cells were photo-irradiated with 660nm laser (3.5mW/cm2) for 
0, 5, 10, 20 and 30min (0, 1.05, 2.1, 4.2 and 6.3J/cm2), respectively. After 48hrs, cell 
viability was measured using Alamar Blue Assay.
To investigate the effect of receptor inhibitor on the RGD-P-Ce6 mediated PDT, A375 cells 
were treated with RGD-P-Ce6 (50nM) in the absence and presence of the inhibitor cRGDfV 
(10μM) for 12hrs. Then cells were rinsed twice with fresh culture media and photo-
irradiated with 660nm laser (3.5mW/cm2) for 30min, respectively. After 48hrs, cell viability 
was measured using Alamar blue Assay.
2.9 Penetration and phototoxicity of RGD-P-Ce6 in tumor spheroids
For spheroids generation, A375 cells were seeded into ultra-low attachment 96-well round 
bottom plates (Thermo Scientific) at the density of 8,000 cells in 100μl media and cultured 
for 3 days. To detect the penetration of the nanoconjugates in spheroids, medium was 
replaced with fresh medium containing free Ce6 and RGD-P-Ce6 at the concentrations of 
200, 400 and 800nM. After 24hrs, the spheroids were digested into single cells and the Ce6 
fluorescence in A375 cells was detected by flow cytometry using BD LSR II. For confocal 
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imaging, the spheroids treated by free Ce6 and RGD-P-Ce6 were fixed in 4% 
paraformaldehyde and were then mounted on a slide with fluoromount G (Electron 
Microscopy Sciences, Hatfield, PA). The spheroids were imaged using Olympus FV1200 
confocal microscope to collect Z stack images, preceding every 10μm until laser penetration 
faltered (~190μm in depth).
To examine the phototoxicity, A375 spheroids were treated with Ce6 and RGD-P-Ce6 
(800nM) for 24hrs. Then the spheroids were rinsed with fresh culture medium and incubated 
for another 1hr before photo-irradiation (660nm laser, 3.5mW/cm2 and 30min). Images of 
the spheroids were captured using microscope. Four days after photo-irradiation, cell 
viability of the spheroids was measured using Alamar Blue Assay.
2.10 Data analysis
Data are expressed as mean ± SD from three measurements unless otherwise noted. 
Statistical significance was evaluated using t-test for two-sample comparison or ANOVA 
followed by Dunnet’s test for multiple comparisons. The data were analyzed with GraphPad 
Prism 5 (GraphPad Software, Inc., La Jolla, CA).
3. Results
3.1 Physicochemical characterization of RGD-P-Ce6
The zeta potential of PEG-P-Ce6 and RGD-P-Ce6 were +2.9mV and +0.8mV, respectively 
(Fig. 1b, Sfig. 2). The TEM image of RGD-P-Ce6 showed well dispersed spherical 
morphology (Fig. 1c). The average hydrodynamic diameter of PEG-P-Ce6 and RGD-P-Ce6 
measured by DLS was 20nm and 28nm, respectively (Fig. 1a, Sfig. 3). The number of Ce6 
linked to each dendrimer was estimated to be approximately 6.5 based on quantitation of 
Ce6 content in final product using UV spectrometry.
The UV/vis absorption of RGD-P-Ce6 showed two main peaks at 405 and 661nm (Sfig. 4), 
which was similar to free Ce6. The fluorescence of free Ce6 dissolved in methanol is 
significantly higher than that diluted by water, likely due to formation of aggregation in 
aqueous solution. The fluorescence of RGD-P-Ce6 in aqueous solution is higher than free 
Ce6 dissolved in water (Sfig. 5), which may indicate that conjugation to PAMAM dendrimer 
prevents intermolecular aggregation of Ce6 that dramatically decreases the Ce6 
fluorescence.
To investigate the photo-activity of RGD-P-Ce6 in aqueous solution, the fluorescence of 
SOSG before and after photo-irradiation was measured. The singlet oxygen yield of RGD-P-
Ce6 in aqueous media was approximately 2.5-fold higher than that of free Ce6 (Fig. 1d), 
indicating that conjugation of dendrimers prevented Ce6 aggregation and thus maintained its 
photo-activity. Photosensitizers are able to absorb light radiation and eventually transfer that 
energy to the substrate (type I) or molecular oxygen (type II) of photo oxygenation process. 
According to previous studies, free Ce6 or Ce6 conjugates/nanoparticles had a significant 
contribution from type II (singlet oxygen) mechanism for PDT effects.[23–25] The result of 
singlet oxygen production indicated that the photo-activity of RGD-P-Ce6 undergoes a type 
II mechanism.
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3.2 Intracellular uptake of targeted nanoconjugates RGD-P-Ce6
Intracellular uptake of free Ce6, PEG-P-Ce6 and RGD-P-Ce6 was evaluated by incubating 
integrin αvβ3-expressing A375 cells with these molecules for 12hrs and then analysis using 
flow cytometry. The result in Fig. 2a showed that both RGD-P-Ce6 and PEG-P-Ce6 
exhibited significant higher cellular uptake than free Ce6. There was 4.7-fold greater uptake 
of the targeted RGD-P-Ce6 as compared with the non-targeted PEG-P-Ce6 in A375 cells. A 
selective inhibitor of integrin αvβ3 (cRGDfV peptide, 10μM) effectively reduced the uptake 
of RGD-P-Ce6. In addition, uptake of free Ce6, PEG-P-Ce6 and RGD-P-Ce6 was also 
evaluated in integrin αvβ3-negative NIH3T3 cells. As seen in Fig. 2b, PEG-P-Ce6 and 
RGD-P-Ce6 showed similar cellular uptake and cRGD did not cause significant reduction of 
the RGD-P-Ce6 uptake. These observations support the concept that enhanced cellular 
uptake of RGD-P-Ce6 depends on integrin αvβ3 mediated endocytosis.
Endocytosis is the main pathway by which NPs enter cells. The result in Fig. 2c showed that 
cellular uptake of RGD-P-Ce6 by A375 cells was energy-dependent; as the uptake was 
reduced by 94.1% when it was performed at 4°C. Dynamin is a large guanosine 
triphosphatase which regulates both clathrin- and caveolae-mediated endocytosis, and small 
molecule dynasore can specifically inhibit dynamin.[26] In our experiment, dynasore 
reduced the cellular uptake of RGD-P-Ce6 by 98.3%, suggesting that endocytosis of RGD-
P-Ce6 into A375 cells was dependent on clathrin and/or caveolae-mediated endocytosis. 
Chlorpromazine is a blocking agent of clathrin-coated pit formation. It decreased the RGD-
P-Ce6 uptake by 74.3%, indicating the involvement of clathrin-mediated endocytosis in 
RGD-P-Ce6 uptake. Filipin and methyl-β-cyclodextrin are two special inhibitors of 
caveolae-mediated endocytosis. They had a moderate inhibition on the RGD-P-Ce6 uptake 
(10.3% and 19.1%), indicating that caveolae-associated endocytosis was also involved in 
RGD-P-Ce6 uptake but played a minor role. Amiloride and wortmannin, two specific 
inhibitors of macropinocytosis, did not have significant effects on RGD-P-Ce6 uptake, 
indicating that macropinocytosis may not be involved in cellular uptake of RGD-P-Ce6.
3.3 Intracellular localization of RGD-P-Ce6
Intracellular trafficking of RGD-P-Ce6 was studied using confocal microscopy. After 6-hr 
incubation, RGD-P-Ce6 was largely colocalized with the lysosomal marker Lysotracker 
green (Fig. 3), but not with the early endosome marker transferrin (Sfig. 6), indicating that 
RGD-P-Ce6 was transported to the late endosomes/lysosomes after cellular entry. RGD-P-
Ce6 did not located in endoplasmic reticulum (ER) as there was little colocalization between 
RGD-P-Ce6 and ER Tracker Green (Sfig. 7).
3.4 Intracellular singlet oxygen detection during photo-irradiation
To detect the intracellular singlet oxygen generation, A375 cells were treated with CM-
H2DCFDA, a non-fluorescent molecule that can passively diffuse into cells. In the cells, its 
acetate groups are cleaved by intracellular esterase and subsequent oxidation yields a bright 
fluorescent probe that is trapped inside the cell. Fig. 4a showed that RGD-P-Ce6 induced 
production of ROS in A375 cells upon photo-irradiation, and the amount of ROS depended 
on the dose of photo-irradiation (Sfig. 8). In contrast to the increase in singlet oxygen 
generation, the intracellular RGD-P-Ce6 after photo-irradiation gradually decreased upon 
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photo-irradiation (Sfig. 9), indicating Ce6 were degraded by singlet oxygen that was 
produced by itself.
The similar results were obtained by using confocal microscopy. In the group treated by 
RGD-P-Ce6 and CM-H2DCFDA but without photo-irradiation, most of the cells were dim. 
However, bright green fluorescence was observed in most cells after photo-irradiation (Fig. 
4b).
3.5 Apoptosis mediated by RGD-P-Ce6
Cell apoptosis induced by RGD-P-Ce6 mediated PDT was detected using flow cytometry. 
Annexin V-FITC and PI were used as fluorescent probes to distinguish viable cells from 
apoptotic or dead cells. The results in Fig. 5 showed the different cells populations (viable 
(Annexin V-FITC−/PI−), early apoptotic (Annexin V-FITC+/PI−), and late-stage apoptotic or 
dead (Annexin V-FITC+/PI+) were induced by different treatments. After the cells were 
treated with either laser or RGD-P-Ce6 alone, over 97% of the cells were viable. Ten min 
after photo-irradiation, there were 4.4% early apoptotic cells and 1.8% dead cells, 
respectively. After 4 and 12 hrs post photo-irradiation, early apoptotic cells increased to 
14.6% and 25.7%, respectively, and dead cells increased to 5.8% and 25.2%, respectively. 
As time going on, more apoptotic or dead cells appeared in the RGD-P-Ce6 group (Fig. 5 
and Sfig. 10).
3.6 PDT mediated lysosomal leakage
To explore the mechanism of cell apoptosis, we examined the integrity of lysosomes in 
A375 cells after RGD-P-Ce6 treatment followed by photo-irradiation. The Alexa 488-
dextran release-method was used to determine lysosomal leakage as dextran is trapped 
predominantly in the intact lysosomes.[27] As seen in Fig. 6, without photo-irradiation, 
dextran was confined to cytoplasmic vesicles as dots. However, obvious green fluorescence 
diffused into the whole cells when the cells were photo-irradiated with 660nm laser, 
indicating that the lysosomes were where oxidative stress was produced by PDT.
3.7 Cytotoxicity of RGD-P-Ce6 with or without photo-irradiation
To investigate the dark cytotoxicity, free Ce6, PEG-P-Ce6 and RGD-P-Ce6 were added into 
A375 cells at different concentrations (0.4, 0.8, 1.2, 1.6 and 2μM). The result showed that all 
of these three forms of Ce6 did not exhibit obvious cytotoxicity in dark (Sfig. 11).
In order to investigate the photo-cytotoxicity of free Ce6, PEG-P-Ce6 and RGD-P-Ce6, 
A375 and NIH3T3 cells were treated at different concentrations (25, 50, 100, 200, 400 and 
800nM), and were then photo-irradiated with a 660nm laser (3.5mW/cm2) for 30 min. The 
result in Fig. 7a indicated that there was almost no cell killing when A375 cells treated by 
free Ce6 with photo-irradiation, which may be due to the poor cellular uptake of free Ce6. 
However, when irradiated with 660nm laser, RGD-P-Ce6 showed significantly enhanced 
phototoxicity to A375 cells when compared to PEG-P-Ce6 and Ce6. In integrin αvβ3-
negative NIH3T3 cells, PEG-P-Ce6 and RGD-P-Ce6 showed similar phototoxicity upon 
photo-irradiation (3.5mW/cm2) (Fig. 7b).
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To examine the effect of light dose on the phototoxicity of RGD-P-Ce6, A375 cells were 
illuminated with various light doses (0, 1.05, 2.1, 4.2 and 6.3J/cm2) following 12-hr 
incubation with 100nM of RGD-P-Ce6. As shown in Sfig. 12, photokilling of A375 cells by 
RGD-P-Ce6 improved as light dose increased.
To examine the effect of integrin αvβ3 inhibitor on the RGD-P-Ce6 mediated PDT, A375 
cells were treated with RGD-P-Ce6 in the absence and presence of cRGDfV (10μM). As 
shown in Sfig. 13, cRGDfV significantly reduced the phototoxicity of RGD-P-Ce6, 
indicating photokilling by RGD-P-Ce6 depends on integrin αvβ3-mediated cellular uptake.
3.8 Penetration of RGD-P-Ce6 in tumor spheroids
Penetration of Ce6 and RGD-P-Ce6 were examined in A375 tumor spheroids. The results in 
Fig. 8a and Sfig. 14 showed that RGD-P-Ce6 was found throughout the spheroids while the 
free Ce6 exhibited little fluorescence. In the group treated with free Ce6, the profile of the 
flow cytometry histogram shows that the distribution of the free Ce6 was homogeneous in 
spheroids but the level was quite low (Fig. 8b), indicating that free Ce6 could penetrate into 
the spheroids but the cellular uptake was poor. As shown in Fig. 8c, RGD-P-Ce6 (200nM) 
entered about 62.5% cells in spheroids. When the concentration increased to 400nM and 
800nM, the percentage increased to 78% and 88.03%, respectively (Fig. 8d). With the same 
concentrations of 200, 400 and 800nM, RGD-P-Ce6 showed 40.8-, 58.7- and 79.3-folded 
higher cellular uptake than free Ce6, respectively. These results indicated that RGD-P-Ce6 
can penetrate the spheroids deeply and then enter most of the cancer cells.
3.9 Phototoxicity of RGD-P-Ce6 in tumor spheroids
To evaluate PDT effects in tumor spheroids, A375 spheroids were treated with free Ce6 and 
RGD-P-Ce6 (800nM) for 24 hrs and were then irradiated with a 660nm laser. Before photo-
irradiation, there was no obvious difference in control, free Ce6 and RGD-P-Ce6 groups 
(Fig. 9a). Images in RGD-P-Ce6 group showed that there was an obvious physical shrinking 
of the spheroids at Day 1 post photo-irradiation. The spheroids this group did not grow for 4 
days after photo-irradiation (Fig. 9b). The Alamar blue cytotoxicity assay again showed 
significant cell death when compared with control and free Ce6 groups (Fig. 9c). No 
significant difference between untreated and free Ce6 groups was detected in serial 
microscopic observations and the Alamar blue assay.
4. Discussion
To overcome the problems of self-aggregation in aqueous solution and poor tumor delivery 
of hydrophobic photosensitizers, we aimed to construct targeted nanoconjugates that are 
small and non-cytotoxic in dark. Thus, PAMAM dendrimer, Ce6, and cRGD peptides were 
selected as the carrier, therapeutic agent, and targeting ligand, respectively. The RGD-P-Ce6 
nanoconjugates exhibited monodispersed size distribution at 28nm and nearly neutral 
surface charge (+0.8mV). The size of the nanoconjugates is large enough to avoid quick 
renal filtration and is also smaller than conventional NPs so that they may penetrate deeply 
into tumor tissues. In addition, the neutral charge of RGD-P-Ce6 can avoid nonspecific 
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adsorption of proteins on the nanoconjugates surface, which may lead to formation of 
aggregates and thereafter quick clearance from the reticular-endothelial system.
The poor internalization of free Ce6 in serum-containing medium may be due to strong 
binding of Ce6 to serum proteins. In serum-free Opti-MEM media, cellular uptake of free 
Ce6 was dramatically higher than that in serum-containing medium (Sfig. 15). Uptake of 
RGD-P-Ce6 was not affected in the presence of serum (Sfig. 16), indicating that it can avoid 
nonspecific protein binding and thus exhibit superior cancer cell uptake via endocytosis.
Ideally, photosensitizers should be nontoxic in dark to avoid side effects. On the other hand, 
high phototherapeutic efficacy is desirable to completely damage the target cells in disease 
tissues. RGD-P-Ce6 exhibited no toxicity in dark even at the concentration of 2μM, while 
upon photo-irradiation, the IC50 of RGD-P-Ce6 was as low as 25nM (Fig. 7a). When the 
cancer cells were incubated with 400nM RGD-P-Ce6 and photo-irradiated for 30min, the 
viability dramatically decreased to less than 5%. However, at the same concentration of free 
Ce6 (400nM), there was no photo-therapeutic effect. The results indicated that RGD-P-Ce6 
is an effective system to deliver Ce6 to cancer cells to perform PDT.
Previous studies showed that free Ce6 accumulates in several subcellular sites including 
plasma membrane, ER, and lysosome.[28] When Ce6 is conjugated to RGD functionalized 
PAMAM dendrimer, the subcellular localization is limited. RGD-P-Ce6 is internalized by 
cancer cells mainly via the clathrin mediated endocytosis pathway. Upon cellular entry, 
RGD-P-Ce6 entered the late endosomes and lysosomes (Fig. 3). In the lysosomes, singlet 
oxygen generation upon photo-irradiation could be detected in a dose dependent manner of 
photo-irradiation. Singlet oxygen generated in lysosomes causes the destruction of the 
lysosome, leakage of lysosomal contents and finally induction of apoptosis.[29, 30] 
Apoptotic cells can be removed by innate immune system and macrophages and thus tissue 
damage is therefore limited to the photo-irradiated area.[31]
The problem of limited penetration of NPs in tumors has recently received growing 
attention. Some studies have pointed to a minimal particle size of less than 50 nm as a 
requirement for NP penetration.[13, 18] Particle size has a substantial impact on 
pharmacokinetics and biodistribution of NPs, especially on their distribution to tumor sites. 
NPs with the size between 7 to 300nm may have long circulation time in blood because of 
reduced clearance through renal filtration and by the reticuloendothelial system.[32] These 
NPs may have better distribution in leaky sites of tumors due to the EPR effect.[33] 
However, larger particles may have poor delivery to less leaky sites in highly heterogeneous 
tumor tissues.[34] In addition, tumor penetration of larger NPs is largely constrained by 
narrow spacing between tumor cells [35, 36], presence of extracellular matrix, and high 
interstitial fluid pressure.[34, 37] Taken together, smaller NPs (10–50nm) may provide a 
superior delivery system for tumor targeting. In addition, some studies indicated that surface 
charge of NPs also played an important role in spheroids penetration.[38, 39] It showed that 
negative and neutral NPs exhibit greater penetration compared with cationic NPs owing to 
the lack of electrostatic binding to ECM or cells.[40] Moreover, inclusion of peptide RGD 
was also reported to act as a tumor targeting moiety while concurrently enhancing tumor 
tissue penetration.[39, 41] The RGD-P-Ce6 nanoconjugates are targeted neutral NPs with an 
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average size smaller than 50 nm, and thus appear to possess most of the commonly 
characteristics that are necessary for deep tumor penetration. Our initial study using tumor 
spheroids has confirmed excellent tumor penetration of the targeted dendritic 
nanoconjugates.
5. Conclusion
In this study, we successfully prepared targeted nanoconjugates that have shown superior 
PDT effects in cellular tumor models. The nanoconjugates are small in size, neutral and non-
toxic in dark. The RGD functionalized nanoconjugates demonstrated enhanced cellular 
internalization via receptor-mediated endocytosis. In addition, the targeted nanoconjugates 
also exhibited efficient penetration into tumor spheroids. Upon photo-irradiation, the 
nanoconjugates produced sufficient singlet oxygen to induce cell apoptosis in both cancer 
cells monolayer and 3-D spheroids. As a result of their great cellular delivery, small size, 
and lack of dark cytotoxicity, the nanoconjugates may provide an effective tool for targeted 
PDT of solid tumors.
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Characterization of the targeted nanoconjugates RGD-P-Ce6. (a) Particle size distribution 
and (b) Zeta potential. (c) TEM image of RGD-P-Ce6. Scale bar, 100nm. (d) Change in 
SOSG fluorescence due to the generation of singlet oxygen by free Ce6 and RGD-P-Ce6 in 
PBS. PBS with SOSG was photo irradiated for 0, 1, 3, 5 and 10min and set as a negative 
control (n=3).
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Cellular uptake of free Ce6, PEG-P-Ce6 and RGD-P-Ce6 in A375 cells (a) and NIT3T3 
cells (b). (c) Cellular uptake of RGD-P-Ce6 in the presence of various endocytic pathway 
inhibitors. A375 cells were pretreated with the inhibitors 0.5h prior to the incubation of 
RGD-P-Ce6 (n=3), * p<0.05.
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Confocal fluorescence microscopy of A375 cells after treatment with RGD-P-Ce6 and 
Lysotracker Green. (a) Lysosomes labelled by Lysotracker green, (b) RGD-P-Ce6, (c) 
yellow regions indicate localization of RGD-P-Ce6 in the lysosomes and (d) DIC. Scale bar, 
50μm.
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Intracellular singlet oxygen. (a) Flow cytometry detection and (b) Confocal images of ROS 
generation during RGD-P-Ce6 mediated PDT with a cellular ROS probe, CM-H2DCFDA.
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Flow cytometry analysis of A375 cells apoptosis induced by RGD-P-Ce6 mediated PDT.
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Re-distribution of dextran-Alexa 488 induced by RGD-P-Ce6 mediated PDT. Scale bar, 
50μm.
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In vitro phototoxicity of free Ce6, PEG-P-Ce6 and RGD-P-Ce6 in A375 cells (a) and 
NIH3T3 cells (b), n=4, * p<0.05.
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(a) Z-Stack confocal microscopy images of A375 tumor spheroids treated by RGD-P-Ce6 
(800nM) for 24 hrs. Scale bar, 300μm. (b) Flow cytometry of the digested cells of tumor 
spheroids treated by free Ce6 (200,400 and 800nM) for 24 hrs. (c) Flow cytometry of the 
digested cells of tumor spheroids treated by RGD-P-Ce6 (200,400 and 800nM) for 24 hrs. 
(d) Percentage of A375 cells in spheroids labelled by free Ce6 and RGD-P-Ce6.
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Tumor spheroids. Images (a), volume (b) and cell viability (c) of tumor spheroids treated by 
free Ce6 and RGD-P-Ce6 mediated PDT. Untreated spheroids photo-irradiated by laser were 
set as control (n=3), Scale bar, 300μm, * p<0.05.
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